Scientific Online Resource System

Social Medicine

Overview of the quality aspects and regulatory frame of the non-interventional studies

Emil Kostov, Hristina Lebanova, Evgeni Grigorov

Abstract

Unmet medical needs require the development of new medicines and health technologies. Non-interventional studies (NIS) are one of the most effective ways to obtain real-world additional information regarding drug efficacy, effectiveness, and safety. These studies are conducted with approved medicines and within the scope of their standard use, aiming at collecting additional drug safety information from patients and healthcare professionals. A good understanding of NIS requires a clear distinction between them and clinical trials. European regulatory documents in the field of clinical trials are not applicable to non-interventional studies due to the lower risk of their conduct, but country-specific regulation is used instead. The national legal framework governing public relations related to clinical trials and non-interventional studies is diverse and includes a large number of regulations, which is a prerequisite for inconsistency in its application


Keywords

clinical trial; non-interventional study; post marketing; medicinal product

Full Text


References

Lebanova H., Getov I., Grigorov E. S V. Look-alike medicines in Bulgaria-source medication errors and potential risks in clinical pharmacy practice. Int J Clin Pharm. 2012;34 (1):165.

Getova V. Overview of regulation and quality aspects of conducting clinical trials and medicinal product use in real-life practice. Ann Hosp Pharm. 2019;5(1):51–60.

Европейски Парламент. ДИРЕКТИВА2001/20/ЕО НА ЕВРОПЕЙСКИЯ ПАРЛАМЕНТ И НА СЪВЕТА. 2001г. 20 с.

Народно събрание. Закон за лекарствените продукти в хуманната медицина. Обн. ДВ 2007 г.

Benson K, Hartz AJ. A Comparison of Observational Studies and Randomized, Controlled Trials. N Engl J Med. 2000 Jun 22;342(25):1878–86.

Министерство на здравеопазването. Наредба № 31 от 12 август 2007 г. за определяне на правилата за добра клинична практика. Обн. ДВ 2007г.

ICH. Guidelines for good clinical practice E6 (R1). 1996. 2–16 p.

EMA. ENCEPP CONSIDERATIONS ON THE DEFINITION OF NON-INTERVENTIONAL TRIALS UNDER THE CURRENT LEGISLATIVE FRAMEWORK. 2011;44(0).

Стоименова А, Манова М, Драганов Г, Петрова Г. Законодателно регламентиране на клиничните изпитвания в България. Med Biol Stud. 2009;3:29–33.

Народно събрание. Закон за здравното осигуряване. Обн. ДВ 2002г.

Народно събрание. Закон за контрол върху наркотичните вещества и прекурсотите. Обн. ДВ 1999г.

Народно събрание. Закон за медицинските изделия. Обн. ДВ 2007г.

Народно събрание. Закон за съсловните организации на лекарите и на лекарите по дентална медицина (загл. изм. - дв, бр. 76 от 2005 г., в сила от 01.01.2007 г.). Обн. ДВ 2007.

Министерство на здравеопазването. Наредба № 28 за устройството, реда и организацията на работата на аптеките и номенклатурата на лекарствените продукти. Обн. ДВ 2008.

Министерство на здравеопазването. Кодекс на професионалната етика. Обн. ДВ 2000г.

Европейски Парламент. Директива 2001/20/ЕО. 2001г.

Европейски Парламент. Директива 2005/28/ЕО на Комисията. 2005.

Mccully S, Compliance R. Conducting non-interventional studies in Europe. 2016;1–12.

Theobald K, Capan M, Herbold M, Schinzel S, Hundt F. Quality assurance in non-interventional studies. Vol. 7, German medical science: GMS e-journal. 2009. p. 29.

WHO. The importance of Pharmacovigilance. Geneva; 2002.

Mccully S. Non-Interventional Studies : Europe (Part 2). CHCUK, 2011 ISBN: 9780956331939.

European Commission. EudraLex - Volume 10 - Clinical trials guidelines. 2017.

Vekov T, Grigorov E, Dzhambazov S. An analysis of regulatory guidelines and good practices of pharmacoeconomic assessments - Recommendations for application in Bulgaria. Gen Med. 2015;17(1).




DOI: http://dx.doi.org/10.14748/sm.v31i1.10217

Refbacks

Font Size


|